Liquid Biopsy Detects Relapse Five Months Earlier than Regular Clinical Follow-Up and Guides Targeted Treatment in Breast Cancer

Figure 1

ctDNA analysis detects disease recurrence in a breast cancer patient five months before clinical recurrence. Levels of the tumor markers CA-153 and carcinoembryonic antigen (CEA) are displayed. The detection of ctDNA mutations and liver metastases, as well as the initiation of everolimus therapy, is indicated by red arrows.